Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244646 | 0.83 | KDM4E (0.50) | KDM4ENPC1RAB9AMAPTELANE | |
| SCHEMBL16244878 | 0.81 | KDM4E (0.48) | KDM4ENPC1RAB9AMAPTELANE | |
| SCHEMBL16244305 | 0.78 | S1PR1 (0.39) | KDM4ENPC1RAB9AMAPTKMT2A | |
| SCHEMBL16244917 | 0.78 | MAPT (0.43) | KDM4ENPC1RAB9AMAPTELANE | |
| SCHEMBL16244220 | 0.77 | BRD4 (0.38) | KDM4ENPC1RAB9AMAPTGABRA2 | |
| SCHEMBL16244258 | 0.77 | BRD4 (0.39) | KDM4ENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL16244489 | 0.75 | NPBWR1 (0.45) | KDM4ENPC1RAB9AMAPTGABRA2 | |
| SCHEMBL15145571 | 0.74 | TARBP2 (0.40) | KDM4ENPC1RAB9AMAPTELANE | |
| SCHEMBL25302211 | 0.74 | NPC1 (0.42) | KDM4ENPC1RAB9AELANESMN1; SMN2 | |
| SCHEMBL16244645 | 0.74 | KDM4E (0.40) | KDM4ENPC1RAB9AMAPTELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004110-B1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| EP-3004110-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| WO-2014191896-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | PKD1, PKD2, REN | KDM4E 2902/4885NPC1 326/4885RAB9A 1126/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | KDM4E 2965/4885NPC1 327/4885RAB9A 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.